Max Salm
Research Subjects
Max Salm has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Charlotte Boulton
Research Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom
3 shared publications- Hugh O'BRien
Achilles Therapeutics Ltd, London, UK
3 shared publications - Sergio A. Quezada
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK
3 shared publications - Sine Reker Hadrup
Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark
3 shared publications - Charles Swanton
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK
2 shared publications Felix O’fArrell
Achilles Therapeutics Ltd, London, UK
2 shared publications
Latest Publications
- Open Access
- 11 November 2024
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 20 (11) , e1012511
A modular protein language modelling approach to immunogenicity prediction
Neoantigen immunogenicity prediction is a highly challenging problem in the development of personalised medicines. Low reactivity rates in called neoantigens result in a difficult prediction scenario with limited training datasets. Here we describe ImmugenX, a modular protein language modelling approach to immunogenicity prediction for CD8+ reactive epitopes. ImmugenX comprises of a pMHC encoding module trained on three pMHC prediction tasks, an optional TCR encoding module and a set of context specific immunogenicity prediction head modules. Compared with state-of-the-art models for each task, ImmugenX’s encoding module performs comparably or better on pMHC binding affinity, eluted ligand prediction and stability tasks. ImmugenX outperforms all compared models on pMHC immunogenicity prediction (Area under the receiver operating characteristic curve = 0.619, average precision: 0.514), with a 7% increase in average precision compared to the next best model. ImmugenX shows further improved performance on immunogenicity prediction with the integration of TCR context information. ImmugenX performance is further analysed for interpretability, which locates areas of weakness found across existing immunogenicity models and highlight possible biases in public datasets.
- 11 November 2024
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 20 (11) , e1012511
Open AccessA modular protein language modelling approach to immunogenicity prediction
Neoantigen immunogenicity prediction is a highly challenging problem in the development of personalised medicines. Low reactivity rates in called neoantigens result in a difficult prediction scenario with limited training datasets. Here we describe ImmugenX, a modular protein language modelling approach to immunogenicity prediction for CD8+ reactive epitopes. ImmugenX comprises of a pMHC encoding module trained on three pMHC prediction tasks, an optional TCR encoding module and a set of context specific immunogenicity prediction head modules. Compared with state-of-the-art models for each task, ImmugenX’s encoding module performs comparably or better on pMHC binding affinity, eluted ligand prediction and stability tasks. ImmugenX outperforms all compared models on pMHC immunogenicity prediction (Area under the receiver operating characteristic curve = 0.619, average precision: 0.514), with a 7% increase in average precision compared to the next best model. ImmugenX shows further improved performance on immunogenicity prediction with the integration of TCR context information. ImmugenX performance is further analysed for interpretability, which locates areas of weakness found across existing immunogenicity models and highlight possible biases in public datasets.
- Open Access
- 15 April 2024
- Published by Springer Nature in Nature Cancer
- Vol. 5 (4) , 692
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction
- 15 April 2024
- Published by Springer Nature in Nature Cancer
- Vol. 5 (4) , 692
Open AccessAuthor Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction
- 15 December 2023
- Published by Springer Nature in Nature Cancer
- Vol. 4 (12) , 1618-1621
Breaking the performance ceiling for neoantigen immunogenicity prediction
- 15 December 2023
- Published by Springer Nature in Nature Cancer
- Vol. 4 (12) , 1618-1621
Breaking the performance ceiling for neoantigen immunogenicity prediction